New Ebola vaccine trial in Uganda aims to target all strains of the virus
The study will take place at the Epicentre Mbarara research centre in Uganda, will last for two years and will include 800 healthcare and frontline workers
09 August 2019 - 08:08
In August 2015 Dr Sakoba Keita, who led the Ebola response in Guinea during the largest Ebola outbreak the world has ever seen, declared, “The Ebola vaccine is a gift from Guinea to West Africa and the world.”
This was just after the preliminary results of the “Ebola ça suffit” trial that proved the safety and efficacy of the rVSV Zebov vaccine produced by Merck and currently being used in the Democratic Republic of Congo (DRC)...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.